Many therapies used today fail to provide the right balance of efficacy, safety, duration and convenience for patients.
Eupraxia was founded to develop therapies to solve that problem.
A technology that is designed to precisely deliver drugs to diseased tissues avoiding exposure to the rest of the body.
A patient-centric approach, targeting areas of greatest need to help people and their healthcare providers achieve the best outcomes.
A driven team of medical and engineering experts integrating deep formulation, clinical and regulatory experience, with a commitment to delivering results and improving patient outcomes.
Our Technology
At the heart of Eupraxia’s innovation is Diffusphere™, a proprietary delivery technology focused on extended-release formulations that are designed to act directly at the site of disease. Diffusphere is designed to improve treatment outcomes, reduce side effects, and simplify care. We believe the technology is poised to shift the current drug delivery paradigm by solely targeting diseased cells in inflammatory diseases, oncology, pain and other conditions.
Our Pipeline
Eupraxia is building a clinical pipeline for impact, addressing high-need, underserved indications in gastrointestinal and musculoskeletal diseases. We are working to prove the power of Diffusphere, potentially offering long-term relief with a single treatment for eosinophilic esophagitis and joint disorders, both global multibillion-dollar markets where the current standard of care underdelivers.
Eosinophilic Esophagitis (EoE) is a chronic and progressive disease of inflammation in the esophagus. Today, the disease affects almost half a million people in the US alone; we estimate the US-based EoE population to be more than one million patients by 2029.
Eupraxia’s EP-104GI for EoE is designed to deliver targeted, sustained anti-inflammatory therapy directly to the esophagus, with the potential to reduce symptoms and tissue damage with fewer doses and fewer trade-offs.
Market Potential
Combined global market potential across EoE and joint pain, two high-need areas where current treatments fall short.
Technology
A technology that is designed to precisely deliver drugs to diseased tissues avoiding exposure to the rest of the body.
Clinical Programs
A strong clinical foundation demonstrating the versatility and commercial potential of our Diffusphere technology.
Management
A team with deep expertise in formulation design and development, clinical studies, regulatory strategy, and commercial planning.
Latest News
September 2, 2025
At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GI All Cohorts followed to 9 months have maintained clinically meaningful improvements in tissue health as measured by EoE Histological Scoring System (“EoEHSS”) No
August 12, 2025
Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026 Announced positive data from Phase 1b/2a RESOLVE supporting the potential of EP-104GI to improve the standard of care for patients with Eosinophilic
July 22, 2025
VICTORIA, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize local, controlled drug delivery for
Eupraxia is a clinical-stage biotechnology company developing targeted therapies that leverage a proprietary extended-release delivery system to provide the right dose of a drug in the right place for the right amount of time.
Eupraxia Pharmaceuticals
201-2067 Cadboro Bay Rd.
Victoria BC, Canada, V8R 5G4